What the FDA labels say about taking them together
Bictegravir/emtricitabine/tenofovir alafenamide and dofetilide
Bictegravir/emtricitabine/tenofovir alafenamide's FDA label of April 30, 2024 names dofetilide in its contraindications section; the dofetilide label PlainMeds reads does not name bictegravir/emtricitabine/tenofovir alafenamide. The bictegravir/emtricitabine/tenofovir alafenamide label: “Coadministration of BIKTARVY with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations (see Table 3 ).”
Check it at the source: the bictegravir/emtricitabine/tenofovir alafenamide FDA label on DailyMed (effective April 30, 2024, A-S Medication Solutions); the dofetilide FDA label on DailyMed (effective April 21, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the bictegravir/emtricitabine/tenofovir alafenamide label say about dofetilide?
Bictegravir/emtricitabine/tenofovir alafenamide label, contraindicationsCONTRAINDICATIONS BIKTARVY is contraindicated to be co-administered with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events [see Drug Interactions (7.5) ]. rifampin due to decreased BIC plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to BIKTARVY [see Drug Interactions (7.5) ].
Bictegravir/emtricitabine/tenofovir alafenamide label, drug interactionsCoadministration of BIKTARVY with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations (see Table 3 ).
Source: FDA drug label (Biktarvy), NDA210251 (Gilead Sciences Inc), as published by A-S Medication Solutions, effective April 30, 2024 (SPL set 0476d7eb-1024-4821-bbe7-abaacfda32a2), via openFDA; the full label on DailyMed
What does the dofetilide label say about bictegravir/emtricitabine/tenofovir alafenamide?
Dofetilide's label (effective April 21, 2026) does not name bictegravir/emtricitabine/tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tikosyn), Pfizer Laboratories Div Pfizer Inc, effective April 21, 2026 (SPL set 02438044-d6a3-49e9-a1ac-3aad21ef2c8c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bictegravir/emtricitabine/tenofovir alafenamide | Dofetilide | |
|---|---|---|
| Labeled for | HIV | Atrial fibrillation |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $136.73 per tablet 50-200-25 mg tablet | $0.203 per capsule 125 mcg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once